Efficacy and impact on serum markers of almonertinib and furmonertinib in patients with non-small cell lung cancer
Sun Mengying
Ouyang Surui
He Jingdong
Jiang Chao
Abstract：Objective To investigate the efficacy of almonertinib and furmonertinib in patients with non-small cell lung cancer(NSCLC)and the effects on the levels of serum microRNA(miR)-499 and miR-144-3p.Methods A total of 94 patients with ad-vanced NSCLC admitted to the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University from January 2021 to Jan-uary 2024 were selected and divided into the almonertinib group(47 cases)and the furmonertinib group(47 cases)using a random number table method.The almonertinib group received oral treatment with almonertinib mesylate tablets,while the furmonertinib group received oral treatment with furmonertinib mesylate tablets.The clinical efficacy,the serum levels of miR-499,miR-144-3p,IgA,IgM and IgG before and after treatment,the incidence of adverse reactions,and the 1-year survival status were observed in both groups.Results There was no significant difference in the objective response rate(48.94%vs 55.32%)and disease control rate(80.85%vs 85.11%)between the almonertinib group and the furmonertinib group(χ2=0.384,0.301,both P>0.05).After treatment,the relative expression levels of miR-499 and miR-144-3p were(0.86±0.23)and(0.96±0.18)in the almonertinib group,and(0.92±0.25)and(1.02±0.20)in the furmonertinib group,all of which were higher than(0.68±0.18)and(0.81±0.21)in the almonertinib group,and(0.75±0.21)and(0.86±0.19)in the furmonertinib group before treatment.The levels of IgA,IgG and IgM were(1.11±0.2)g·L-1,(5.38±0.42)g·L-1 and(1.56±0.22)g·L-1 in the almonertinib group,and(1.04±0.17)g·L-1,(5.24±0.31)g·L-1 and(1.49±0.18)g·L-1 in the furmonertinib group,lower than(1.42±0.25)g·L-1,(8.02±1.21)g·L-1 and(1.84±0.33)g·L-1 in the almonertinib group,and(1.48±0.31)g·L-1,(7.73±1.38)g·L-1 and(1.77±0.31)g·L-1 in the furmonertinib group before treatment.There were no significant dif-ferences in the relative expression levels of miR-499 and miR-144-3p,and the levels of IgA,IgG,and IgM between the two groups before and after treatment(t=1.735,1.211,1.210,1.529,1.033,1.776,1.083,1.839,1.060,1.688,all P>0.05).There was no signif-icant difference in the incidence of adverse reactions between the two groups(Fisher's exact test,P>0.05).The 1-year survival rate in the furmonertinib group was higher than that in the almonertinib group and the difference was statistically significant(χ2=5.934,P=0.015).The median progression-free survival was longer in the furmonertinib group than that in the almonertinib group and the difference was statistically significant(Log-rank χ2=8.444,P=0.004).Conclusion Both almonertinib and furmonertinib have sim-ilar clinical efficacy and safety in treating NSCLC and can effectively regulate the levels of serum miR-499,miR-144-3p and immu-noglobulins.However,furmonertinib is more effective in prolonging patients'survival.
Keywords：Non-small cell lung cancerAlmonertinibFurmonertinibMicroRNA-499MicroRNA-144-3p
Publication Date：2025-06-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 375-378 )